Data Collection

(1) Baseline characteristics: Age; sex; underlying diseases, including hypertension, diabetes, and coronary heart disease (CHD); etiology supporting the use of ECMO; hemodynamic data such as mean arterial pressure (MAP) and Central Venous Pressure (CVP); biochemical indexes (blood gas analysis, blood biochemistry, coagulation function, blood routine) 24 h post-ECMO support; assessment of severity after ECMO support for 24 h, including Acute Physiology and Chronic Health Evaluation II (APACHE-II) score, Sequential Organ Failure Assessment (SOFA) score; and other interventions, including percutaneous coronary intervention (PCI), intra-aortic balloon pump (IABP), mechanical ventilation (MV), and continuous renal replacement therapy (CRRT).

(2) ECMO-related characteristics: Location of ECMO, duration of building ECMO, vasoactive inotropic score [VIS = dose of dopamine + dose of dobutamine + 100 × dose of epinephrine + 10 × dose of milrinone + 10,000 × dose of vasopressin + 100 × dose of norepinephrine (unit: μg/kg/min)], duration of non-pulsatile perfusion (NP) after ECMO support, ECMO duration, mechanical ventilation parameters, complications, dosage of blood product [red blood cell (RBC) and fresh frozen plasma (FFP)], and weaning from ECMO

(3) Outcome indicators: Intensive Care Unit (ICU) length of stay (LOS), hospital LOS, 28-day mortality, incidence of neuropathy and mortality after discharge.

(4) Data processing: The epidemiology, clinical features, and related risk indicators connected with the identified neurological complications are discussed through the analysis of the above data.